PRISM BioLab develops small-molecule inhibitors that target protein–protein interactions (PPIs) using its proprietary PepMetics® chemistry platform. PepMetics® are chemical scaffolds that mimic three-dimensional alpha‑helix and beta‑turn peptide structures commonly found at PPI interfaces, and the company combines this chemistry with AI‑supported design. PRISM has spent over a decade developing these scaffolds to enable systematic and reproducible discovery of drugs against challenging PPI targets, with the goal of creating oral small‑molecule alternatives to injectable biologics. The company is collaborating with global and Japanese pharmaceutical firms, and PepMetics® programs targeting CBP/beta‑catenin PPIs have been licensed to Eisai and Ohara and are in clinical development for cancer and liver disease. PRISM plans to use the new funding to refine its PepMetics® chemistry platform, expand biology and screening capabilities, and advance its internal pipeline. The financing totaled ¥1.5 billion ($10.3M) and included participation from Eli Lilly and Santec Holdings Corporation.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2024